| Name | Title | Contact Details |
|---|
Founded in 1985, Clinical Research Dental is the proud Canadian distributor for a number of internationally renowned dental manufacturers, including Clinician`s Choice, Ultradent, Bioclear, 3M, Cosmedent, Triodent, Komet and Ribbond. The company is also a leading provider of continuing education programs for dentists, and hosts 40 to 50 seminars and hands-on courses across Canada each year.
Community Products is a Rifton, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Medicorp Inc is a Mont-Royal, QC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Simavita is a medical device company operating in the digital healthcare sector that has developed an innovative world first solution for the management of urinary incontinence, with a focus on the elderly. Our flagship product is the SIM™ platform technology, an instrumented Incontinence assessment application that provides evidence based Incontinence management care plans to the residential aged care market. Simavita is committed to continuously innovating and expanding its core SIM™ platform technology to improve the level of Incontinence care, create efficiencies, promote effective utilisation of our society`s finite resources and enhance the dignity of care for our ageing population.
OXiGENE is a biopharmaceutical company developing new and improved therapeutics that have the potential to deliver significant medical benefits to patients with cancer and serious medical conditions. Our primary focus is developing first-in-class anti-vascular drugs referred to as vascular disrupting agents (VDAs). Our lead compound in clinical development is fosbretabulin. VDAs are a new and highly differentiated class of anti-vascular drug that target existing tumor vasculature, leading to extensive tumor cell death. VDAs target the tumor vasculature rather than the tumor cells and therefore have broad potential therapeutic utility in cancer. Because VDAs act differently than anti-angiogenic drugs or cytotoxic chemotherapy drugs, VDAs are potentially complementary with anti-angiogenic drugs and chemotherapeutic agents. OXiGENE has ongoing VDA drug development programs and is committed to advancing the science of VDAs and their potential as innovative therapies to address unmet medical needs.